Security Force Crackdown

Showing 1301 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

Fastly's AI-Driven Rally: Sustainable Momentum or Short-Lived Hype?

Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.

Business

ManpowerGroup Sees 'Stabilization' in Q4 as Demand Firms, Cost Cuts Take Hold

ManpowerGroup reported a return to modest organic growth in its fourth quarter, with executives citing improving demand and the benefits of ongoing cost optimization. While stopping short of declaring a broad recovery, the staffing giant highlighted sequential improvements in key markets and pointed to AI-driven productivity tools as a key differentiator.

Business

Future PLC's Five-Year Plunge: A 70% Loss Tests Long-Term Investment Faith

While long-term investing is a cornerstone strategy, the dramatic 70% share price collapse at Future PLC over five years serves as a stark reminder that time alone doesn't guarantee returns. This analysis delves beyond the headline numbers to examine the puzzling disconnect between the company's operational metrics and its market valuation.